Recently, the annual meeting of the American Society of Clinical Oncology (ASCO) is in hotcy in Chicago. In just a few days, we have seen many exciting new achievements in cancer. Today, in this inventory, we are sending you some data that is widely concerned by the industry.
Reduced risk of disease progression by 42%, AstraZeneca PARP inhibitor Lynparza's first breast cancer stage 3 clinically demonstrated positive efficacy
AstraZeneca (AstraZeneca) announced that in its Phase 3 OlympiAD clinical trial, patients with the PARP inhibitor Lynparza (olaparib) had significantly longer progression-free survival compared with breast cancer patients who received standard chemotherapy. There has been a clinically meaningful improvement. It is worth mentioning that this is the first time that olaparib has shown positive effects in cancers other than ovarian cancer in Phase 3 clinical trials.
Breast cancer patients enrolled in this study were HER2-negative and carried BRCA1 or BRCA2 germline mutations. After breast cancer metastasis, they received first-, second-, or third-line treatment with olaparib. A blinded independent review (BICR) found that patients who used olaparib had a 42% lower risk of disease progression or patient death compared with patients who received chemotherapy (HR 0.58, 95% CI 0.43 – 0.80, p=0.0009. The median was 7.0 months vs. 4.2 months). These data reached the main clinical endpoint.
"The results of OlympiAD mark the first time that targeted therapies will provide better benefits for HER-2 negative, metastatic breast cancer patients with BRCA germline mutations, in addition to existing standard care regimens," AstraZeneca Dr. Sean Bohen, Executive Vice President and Chief Medical Officer of Global Drug Development, said: "This is an important milestone for Lynparza and a phase 3 clinical trial in which PARP inhibitors have shown significant efficacy in other patient populations for the first time in addition to ovarian cancer. ."
21% of patients have complete intracranial remission, BMS tumor immunotherapy combination announced 2 latest data
Bristol-Myers Squibb (BMS) announced in Phase 2 clinical data from Phase 2 of the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) in the treatment of melanoma brain metastases. This is also the first phase 2 study to evaluate this immunotherapy in this patient population. The primary end point of the study was the intracranial (IC) clinical benefit rate (CBR), the proportion of patients with complete remission, partial remission, and disease stabilization ≥ 6 months. Of the 75 patients evaluated, CBR was 60% (95% CI: 0.48-0.71) after a median follow-up of 9.2 months.
In this CheckMate-204, 21% (n=16) of patients achieved complete intracranial remission; 33% (n=25) of patients achieved partial remission; 5% (n=4) of patients achieved stable disease. The intracranial objective response rate (ORR) was 55% (95% CI: 43-66), and the safety was consistent with the safety data of previously reported melanoma patients without brain metastases.
"CheckMate-204 clinical research is of great importance because studies of advanced melanoma with brain metastases are relatively limited, and such patients have often been unable to participate in clinical studies," said Vick Goodman, head of melanoma and genitourinary tumor research and development at Bristol-Myers Squibb. According to the doctor, “These data are an important complement to the scientific understanding of nivolumab and ipilimumab, reflecting the commitment of Bristol-Myers Squibb to joint treatment research, and we will continue to explore the potential benefits of this therapy for different patient populations.â€
1. Considering the limitation of storage space and storage cost, as well as the fact that video recording in public places such as residential areas is a prerequisite for multi slot and a certain degree of clarity, video recording is generally deleted once a week or so. 15 days for general entertainment venues, 26 days for financial industry, and 3 months to half a year for banks, depending on the current venue regulations
2. The length of the storage time of the monitoring video is generally related to the following points: the capacity of the host's hard disk. Generally, a camera needs about 0.3G-0.5G of hard disk capacity for 24 hours of continuous video recording. Different systems have different parameters, the minimum is 0.15G/24 hours;
3. The number of cameras. The more cameras, the more capacity required. Also, the selection of the resolution and picture quality of the recorded picture will also affect the capacity required for video storage;
4. The video recording mode will also affect the space required for storage. The video recording mode is generally divided into [Mobile Video Recording] and [Continuous Video Recording]. The former means that the host starts to record when a moving object passes through the monitoring range, and does not record at other times. This can reduce the storage space required for video recording; On the contrary, continuous video recording is 24-hour continuous video recording.
Doorbell Camera,360 Degree Camera, Night Vision Security Camera, Security IP Camera
Shenzhen Fuvision Electronics Co., Ltd. , https://www.szsolarcamera.com